RowLabel	52427085060	52427089060
NDC11	52427085060	52427089060
Trade Name	Gralise Tablets, 750mg	Gralise Tablets, 900mg
Chemical Name	gabapentin	gabapentin
Product introduction date	4/25/2023	4/25/2023
Wholesale Acquisition Cost (WAC) per package	\$957.72	\$957.72
Wholesale Acquisition Cost (WAC) per treatment course	\$957.72	\$957.72
Description of the marketing and pricing plans used in the launch of the new		
drug in the United States and internationally	Gralise is promoted by our commercial field team to healthcare professionals	
	to educate them on our product. We use various means of promotion	Gralise is promoted by our commercial field team to healthcare professionals
	including in-office visits, virtual meetings, and non-personal digital marketing.	
	A website www.gralise.com provides further information about Gralise.	including in-office visits, virtual meetings, and non-personal digital marketing.
	Almatica considers various factors in deciding the wholesale acquisition cost	
	(WAC) at which to set its prescription drugs, including Gralise. These factors	•
	include, but are not limited to: market based factors such as the competitive	
	landscape and pricing environment; manufacturing and supply	include, but are not limited to: market based factors such as the competitive
	considerations; profitability; inflation and costs, including increased cost of	landscape and pricing environment; manufacturing and supply considerations;
	administrative and commercial activities; therapeutic class and patient	profitability; inflation and costs, including increased cost of administrative and
	population, as well as patient needs and access; and contracts and	commercial activities; therapeutic class and patient population, as well as
	relationships with customers. Almatica considers various factors in deciding	patient needs and access; and contracts and relationships with customers.
	the wholesale acquisition cost (WAC) at which to set its prescription drugs,	Almatica considers various factors in deciding the wholesale acquisition cost
	including Gralise. These factors include, but are not limited to: market based	· · · · · · · · · · · · · · · · · · ·
	factors such as the competitive landscape and pricing environment;	include, but are not limited to: market based factors such as the competitive
	manufacturing and supply considerations; profitability; inflation and costs,	landscape and pricing environment; manufacturing and supply considerations;
	including increased cost of administrative and commercial activities;	profitability; inflation and costs, including increased cost of administrative and
	therapeutic class and patient population, as well as patient needs and access;	
	and contracts and relationships with customers. Almatica considers various	patient needs and access; and contracts and relationships with customers.
	factors in deciding the wholesale acquisition cost (WAC) at which to set its	Almatica considers various factors in deciding the wholesale acquisition cost
	prescription drugs, including Gralise. These factors include, but are not	(WAC) at which to set its prescription drugs, including Gralise. These factors
	limited to: market based factors such as the competitive landscape and	include, but are not limited to: market based factors such as the competitive
	· · · · · · · · · · · · · · · · · · ·	landscape and pricing environment; manufacturing and supply considerations;
		I profitability; inflation and costs, including increased cost of administrative and
		commercial activities; therapeutic class and patient population, as well as
	The state of the s	
Estimated volume of patients who may be prescribed the drug	and access; and contracts and relationships with customers.	patient needs and access; and contracts and relationships with customers.
, , , ,	and access; and contracts and relationships with customers.  137	patient needs and access; and contracts and relationships with customers.  273
Granted breakthrough therapy designation or priority review by the FDA?		273
Granted breakthrough therapy designation or priority review by the FDA?  Date of acquisition (if acquired)	137	273